Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a CBO analysis.

For years, inspectors have uncovered dirty equipment, contaminated supplies and fraudulent testing records in some overseas factories — serious safety and quality breaches that can sicken or kill ...

An estimated 53 drugs would not enter the market in the next 30 years if the NIH is hit with a permanent 10% budget cut and the FDA experiences a nine-month drug review delay due to staffing cuts, the ...

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and ...

FDA employees are spooked by increasing political involvement in regulatory decisions, frustrated by the impact of cuts to administrative staff who supported drug reviews and inspections, and fed ...

Thousands of health workers lost their jobs this week after a U.S. Supreme Court ruling cleared the way for the Trump ...